Clinical trial Precision 2
An open explorative phase II, open-label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | UZ-Brussel |
| EudraCT Identifier | 2016-003411-34 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03810872 |
| Inclusion criteria | Activating EGFR mutation or HER2 mutation or HER3 mutation |
| Last update |